Little has been reported on the factors, genetic or other, that underlie the variability in individual response, particularly for autism. In this study we simultaneously explored the effects of multiple candidate genes on clinical improvement and occurrence of adverse drug reactions, in 45 autistic patients who received monotherapy with risperidone up to 1 year. Candidate genes involved in the pharmacokinetics (CYP2D6 and ABCB1) and pharmacodynamics (HTR2A, HTR2C, DRD2, DRD3, HTR6) of the drug, and the brain-derived neurotrophic factor (BDNF) gene, were analysed. Using the generalized estimating equation method these genes were tested for association with drug efficacy, assessed with the Autism Treatment Evaluation Checklist, and with safety and tolerability measures, such as prolactin levels, body mass index (BMI), waist circumference and neurological adverse effects, including extrapyramidal movements. Our results confirm that risperidone therapy was very effective in reducing some autism symptoms and caused few serious adverse effects. After adjusting for confounding factors, the HTR2A c.-1438G4A, DRD3 Ser9Gly, HTR2C c.995G4A and ABCB1 1236C4T polymorphisms were predictors for clinical improvement with risperidone therapy. The HTR2A c.-1438G4A, HTR2C c.68G4C (p.C33S), HTR6 c.7154-2542C4T and BDNF c.196G4A (p.V66M) polymorphisms influenced prolactin elevation. HTR2C c.68G4C and CYP2D6 polymorphisms were associated with risperidone-induced increase in BMI or waist circumference. We thus identified for the first time several genes implicated in risperidone efficacy and safety in autism patients. Although association results require replication, given the small sample size, the study makes a preliminary contribution to the personalized therapy of risperidone in autism.
Introduction
Autism is a devastating neurodevelopmental disorder, with no curative therapies available. Treatment approaches to autism generally focus on educational and behavioural interventions. Drug therapy may be used, however, to treat specific disruptive behaviours usually associated with autism (anxiety, irritability, hyperactivity, inattention, obsessive-compulsive symptoms, sleep disturbances, aggression and self-injury), which negatively interfere with the success of educational treatments and quality of family life. 1 According to a recent survey, 31% of children with autism spectrum disorders take an antipsychotic medication, 2 with risperidone one of the most popular atypical antipsychotics prescribed. Several open trials of risperidone in autism (reviewed in 3, 4 ) and three placebo double-blind randomized controlled trials, [5] [6] [7] reported significant improvements in at least half of the patients evaluated. 4, 8 Risperidone was shown to be well tolerated and effective in treating aggressiveness, hyperactivity, irritability, self-injurious behaviours, stereotipies, social withdrawal and lack of interest. According to one study, sensorimotor functioning and affectual relations (abrupt changes in affect, crying, temper outbursts) are also improved. 6, 8 Though risperidone significantly improves behavioural problems in most situations, it is also associated with mild adverse effects. The most common adverse drug reactions (ADR) while taking risperidone are sedation/drowsiness, weight gain, hyperprolactinemia and extrapyramidal symptoms, especially tardive dyskinesias. 4, 8 As with all antipsychotics, there are considerable individual differences in response to risperidone, both regarding therapeutic and adverse effects, imposing some limitations with respect to the therapeutic use of the drug. Little has been reported on the factors, genetic or other, that underlie this individual variability in response to risperidone therapy, particularly for autism. 9 The physiological pathways regulating risperidone action are complex, and involve multiple molecules. The rapid and complete absorption of risperidone after oral administration in the small intestine is mainly mediated by the P-glycoprotein, encoded by the ABCB1 gene, which acts as a barrier to drug absorption. 10 In the liver, risperidone is extensively metabolized by CYP2D6 to the active metabolite 9-OH-risperidone. 11 The CYP2D6 gene is extremely polymorphic and its variants are classified, based on encoded protein activity level, into four different phenotypes, which have a profound influence in the outcome of drug therapy: (1) extensive metabolizers, carry one or two alleles with normal function; (2) intermediate metabolizers, carry two decreased-function alleles or are heterozygous for one deficient allele and one decreased-function allele; (3) poor metabolizers, carry two non-functional alleles; (4) ultrarapid metabolizers, carry multiple copies of functional alleles. 12 In the brain, risperidone binds multiple neurotransmitter receptors, with stronger affinity to the serotonin 2A (5-HT2A) and dopamine D2 receptors, and a good affinity for the a-1 and a-2C adrenergic receptors and for the serotonin receptors 6 and 7 (5-HT6 and 5-HT7). 13 Other molecules may be involved in ADR: the overweight Htr2c knockout mouse 14 suggests an influence of the 5-HT2C receptor, encoded by the HTR2C gene, in risperidone-induced weight gain; several lines of evidence suggest that the brain-derived neurotrophic factor gene (BDNF) is associated with weight regulation and eating behaviour. 15, 16 Furthermore, BDNF has been suggested to have an important function in therapeutic action of antipsychotic medications 17 and evidence for association between BDNF genetic variants and antipsychotic-induced weight gain has been reported. 18, 19 The hypothesis put forward in this study is that the individual variability in response to risperidone in autism, as well as the occurrence of ADRs, is determined by multiple parameters, among which genetic factors have an important impact. We thus tested the influence of 15 genetic variants in 8 genes (HTR2A, HTR2C, HTR6, DRD2, DRD3, ABCB1, CYP2D6 and BDNF) on risperidone efficacy and the occurrence of ADRs, in 45 autistic patients receiving risperidone up to 1 year.
Materials and methods
Forty-five autistic outpatients recruited at the Autism clinic from Hospital Pediátrico de Coimbra (HP), in Portugal were considered eligible for this study. All patients (1) met the algorithm cut-off for the Autism Diagnostic InterviewRevised and Autism Diagnostic Observation Schedule, (2) had a developmental level or intellectual quotient above 30 and functional age above 18 months, (3) had been free of any medication for at least 3 months and (4) presented behavioural alterations of clinical significance in the health/ physical/behaviour subtest of the Autism Treatment Evaluation Checklist (ATEC), scoring as moderate or serious problem on at least two items with no improvement after adequate educational and behavioural intervention. The study was approved by the Ethics Committee at Hospital Pediátrico de Coimbra and agreement to participate in the study was obtained from the legal representative of the patient, who signed an informed consent.
All participants were outpatients who were regularly followed at the autism clinic for at least 1 year. Medication was administered at home by the parents or main caregivers. Risperidone was introduced with progressive increments until satisfactory therapeutic response was reached. The proposed risperidone doses were administered with progressive increments in 2 weeks, according to weight: (i) under 20 kg-beginning with 0.25 mg until a maximum 1.0 mg; (ii) 20-45 kg-beginning with 0.5 mg until a maximum 2.0 mg; (iii) over 45 kg-beginning with 0.5 mg until a maximum 3.0 mg. The drug dose was adjusted to obtain clinical improvement with the minimal occurrence of motor and other side effects.
Drug efficacy and safety assessments were performed at baseline and at defined times after the start of risperidone therapy (1, 3, 6 and 12 months). Evaluation instruments were all rated by the same experienced and extensively trained psychologist, under the supervision of a neurodevelopmental paediatrician, who performed the clinical observation. The primary efficacy measure was the ATEC. 20 Other efficacy measures included the parent version of Nisonger Child Behaviour Rating Form (CBRF) and the Behaviour Problems Inventory (BPI). 21, 22 The ATEC has been specifically designed to evaluate the effectiveness of treatment for autistic individuals. 23, 24 The test consists of a onepage checklist to evaluate the severity of core symptoms of autism as rated by parents or primary caregivers, and is divided into four subtests assessing speech/language/communication, sociability, sensory/cognitive awareness and health physical/behaviour. The range for the total scores is 0-180, with a decline in scores indicating improvement. The CBRF is an informant-based instrument for rating the behaviour of children and adolescents with developmental disabilities, and is divided into two social competence subscales (compliant/calm and adaptive/social) and six problem behaviour subscales (conduct problem, insecure/ anxious, hyperactive, self-injury/stereotyped, self-isolated/ ritualistic and overly sensitive). The BPI is a 52-item respondent-based behaviour rating instrument for selfinjurious, stereotypic and aggressive/destructive behaviour in mental retardation and other developmental disabilities, which assesses both frequency and severity. Drug safety was evaluated by physical (body mass index (BMI), waist circumference) and a classic neurological examination at the same five time points. Serum prolactin level was assessed using the Immulite 2000 prolactin kit. Normality of the distributions of these response values (scale scores, BMI, waist circumference and prolactin levels) was examined using the Shapiro-Wilk test. To evaluate the significance of the variation in response values between the various time points, paired-sample t-test and Wilcoxon test were used, for normal and non-normal distributions, respectively.
At the start of the study, a blood sample was collected for DNA extraction. Genotyping for CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6 gene duplication and ABCB1 rs1128503 (c.1236C4T, p.G412G) and rs1045642 (c.3435C4T, p.I1145I) polymorphisms was performed as described earlier. 25 Marker HTR2A rs6311 (c.-1438G4A) were genotyped according to the method described by Hinney et al. Table 1 ). Only SNPs in Hardy-Weinberg equilibrium at the 5% significance level were further analysed.
To evaluate the influence of the genetic polymorphisms on risperidone effectiveness and tolerability, after adjusting for potential confounding variables, we used the multiple linear regression model. ATEC scores, BMI, waist circumference and prolactin levels were used as response variables. Non-genetic variables that may influence risperidone metabolism, and thus the response to the drug, were used as confounding variables, and included age, sex, dosage, treatment duration and response variable baseline. In repeated measures studies, the longitudinal follow-up data obtained from the same subject are intra-individually related and violate the 'independent' requirement of multiple regression. To adjust this within-subject dependence effect, we used the generalized estimating equation for multiple linear regression in repeated measures studies. 27 An auto-regressive or independent working correlation matrix was specified, assuming a normal distribution with the identity or log link function. Residual analyses indicated whether the models obtained were appropriate. Generalized estimating equation models were developed using a stepwise procedure with the main effects. An initial model with all the confounding variables was obtained and then genetic polymorphisms were repeatedly added or removed from this model, being retained if the Wald test statistic had a P-value lower than 0.05. The genotypes for each polymorphism were grouped into two categories: the first included genotypes homozygous for the most common allele and was used as the reference genotype for the analysis, and the second included genotypes homozygous for the other allele and heterozygous. In the case of CYP2D6, an approximately continuous classification was performed, based on the literature information on CYP2D6 allele activity, 28 and the score equivalent to extensive metabolizers individuals was chosen as the reference. Statistical significance was defined at Po0.05 and was not corrected for multiple testing.
Results
General demographic and clinical data on the 45 autistic children with clinical indication for risperidone therapy are shown in Table 1 . Efficacy and tolerability results for a total of 42 autistic patients, who had completed at least two assessments, on day 0 (before risperidone treatment-T0) and on month 1 (the first posttreatment visit-T1), are shown in Table 2 . The number of patients evaluated on months 3 (T3), 6 (T6) and 12 (T12) were 37, 34 and 31 patients, respectively. Seven of these patients had not reached the 12-month assessment point at the time of analysis. An additional seven patients quit the study before 12 months. The reasons for premature discontinuation were non-compliance (n ¼ 3), apathy (1), poor response (1), sufficient improvement (1) or concurrent somatic illness (1) . No patients withdrew from the trial because of adverse reactions.
Efficacy
The 31 patients that completed 1 year of risperidone therapy (mean dose at T12 ¼ 1.34±0.7, range 0.5-3 mg) had a very significant decrease in the ATEC total score during the 12-month period, which is indicative of a significant improvement (t(30) ¼ 9.48; P ¼ 1.58 Â 10 À10 ) ( Table 3) . Overall, during 1 year of treatment, the mean ATEC total score decreased from 71.4 ± 25.7 to 34.7 ± 23.6 ( Figure 1a) .
The greatest improvements were observed in the behaviour and in the sociability ATEC domains (Figure 1b ). In these subtests, there was a significant improvement overall (t(30) ¼ 14.66; P ¼ 3.21 Â 10 À15 for behaviour; t(30) ¼ 10.24; P ¼ 2.65 Â 10 À11 for sociability) and within every interval, but particularly in the first month (Table 3) . After 1 year of therapy, the mean decreases in behaviour and sociability ATEC scores were 15.5±6.9 and 8.1±3.6, respectively. In the speech and cognitive domains, smaller changes were observed, as expected, although still significant overall
À05 for speech subscale) ( Table 3 ). Improvement as measured by the CBRF score variation was very significant overall, both in the social competence and in the problem behaviour subscales, but particularly on the conduct problem and hyperactive subscales (Table 3) . During the 12-month period, a significant decrease in the BPI scores was also observed, more remarkably in the selfinjurious and aggressive/destructive behaviour subscales (Table 3) . CBRF self-injury/stereotyped and BPI stereotypic behaviour subscales showed less pronounced improvements. The correlations between the ATEC, CBRF and BPI baseline-end point score variations were assessed (Supplementary Table 2 ). Variation in ATEC sociability scores was correlated with the variation in the CBRF social competence subscales scores, and ATEC behaviour subscale change was also highly correlated with the changes in the BPI aggressive/destructive subscale and with all the CBRF subscales, except the hyperactive, self-injury/stereotyped and selfisolated/ritualistic.
Safety and tolerability
Mean BMI at baseline and at end point was 19.29±5.04 and 21.11±5.55 kg m À2 , respectively ( Figure 2 ). Within all the time intervals the increase in BMI was significant, particularly during the first month. The overall increase after 1 year was highly significant (t(28) ¼ 6.85; P ¼ 1.92 Â 10 À07 ) (Table 3) . Accordingly, waist circumference increased very significantly during the 12 months of treatment (t(23) ¼ À9.48; P ¼ 2.05 Â 10 À09 ) ( Table 3 ). Overall, during the 12 months of treatment, there was a mean waist circumference increase of 7.31 ± 2.12 cm (Figure 2 ).
Mean prolactin levels at baseline and end point (T12) were 13.71 ± 12.50 and 34.50 ± 22.39 ng ml À1 . During the first month of treatment there was a significant mean sixfold increase in prolactin levels, but after the first month the levels significantly decrease (Figure2; Table 3 ). Only one child presented clinical symptoms related with hyperprolactinemia, namely galactorrhoea.
No extrapyramidal adverse effects or excessive sedation were observed, with drug dosage adjusted to minimize the occurrence of side effects.
Genetic and non-genetic predictors of drug efficacy and occurrence of ADRs
Genotype frequencies of the tested polymorphisms are shown in Table 4 . After controlling for the confounding factors age, sex, risperidone dose, treatment duration, ATEC baseline scores and other tested genetic variants, several polymorphisms were found to significantly influence the decline in the ATEC scores ( Table 5 ). The ATEC scores of patients with the HTR2A c.-1438G4A AA or AG genotype were 2% lower compared with the patients who had the genotype GG, indicating a greater improvement. Patients with the ABCB1 c.1236C4T TT or CT genotypes had 4.7% lower ATEC scores than CC homozygotes. The DRD3 TT genotype was associated with 3.9% higher scores than the CT or CC genotypes. Regarding HTR2C c.-995G4A, which maps on the X chromosome, patients with the variant genotype (A in man, AA or AG in women) had 4.1% higher ATEC scores compared with the most common genotype (G or GG). Other genetic variables did not significantly influence ATEC scores (data not shown). However, as shown in Table 5 , there are other non-genetic factors that were associated with the clinical performance. For instance, female patients, compared to male, have 5% lower ATEC scores, and baseline ATEC scores significantly influence ATEC outcome.
Genetic and non-genetic factors associated with BMI and waist circumference were the same (Tables 6 and 7) . Age was a significant predictor of BMI and waist circumference increase, with every 1-year increment in patient's age increasing BMI and waist circumference by 0.64 and 0.74%, respectively. As expected, baseline scores also significantly influenced waist circumference and BMI increase. CYP2D6 and HTR2C p.C23S polymorphisms also significantly influenced BMI and waist circumference. Compared with the HTR2C GG homozygotes, patients with the variant genotype (C/C in females; C in males) have 4.6 and 2.8% smaller increases in waist circumference and BMI, respectively. Regarding the CYP2D6, the predicted ultrarapid metabolizers phenotype was associated with a 4.8 and 5.8% lower increase in BMI and waist circumference when compared with the reference extensive metabolizers phenotype. The poor metabolizers phenotype was also associated with a 4% lower increase in waist circumference. Regarding prolactin increase, significant non-genetic predictors include risperidone dose and prolactin baseline levels (Table 8) . After adjusting for these potential confounding factors, several genetic polymorphisms were found to influence the variation in prolactin during risperidone treatment. The presence of the HTR6 rs9659997C allele or the BDNF p.V66M A allele was associated with a higher prolactin increase when compared with the TT and GG genotypes, respectively. Patients with the HTR2A-1438AA or AG genotypes have a smaller prolactin increase than patients with the GG genotype. Finally, women homozygous or men hemizygous for the HTR2C p.C23S G allele had a lower prolactin increase, when compared with individuals homozygous or hemizygous for the C allele.
Discussion
Pharmacogenetic research in autism has been hindered by the lack of instruments that specifically measure the effectiveness of treatments. Evaluation of pharmacological or educational interventions in autism is usually performed using scales designed to diagnose autism that do not specifically measure treatment effectiveness. The ATEC has been developed to evaluate the effectiveness of treatment for autistic individuals and was therefore chosen to assess patient improvement in this study. We found that the variation in the ATEC behaviour and sociability subscales was highly correlated with the social and behaviour items of two other widely used scales (BPI and CBRF). The ATEC total scores also take into account domains that are not evaluated by the BPI and CBRF, such as cognition and speech, and thus provide both a reliable and a more complete measure of the patient's improvement.
The results obtained on the efficacy and safety of risperidone therapy show that medication with this drug is well tolerated and very effective in improving some of the disruptive behaviours commonly associated with autism. Risperidone therapy was also useful in improving the patients social behaviour, as observed earlier in risperidone 
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CT Correia et al randomized controlled trials. [5] [6] [7] 29 These positive effects were maintained at least during 1 year, which was the maximum period evaluated in this study.
As expected from earlier trials, we found a marked increase in BMI, waist circumference and prolactin levels. The mean weight gain observed in our study, over a 6-month period was lower than reported in two earlier studies, 30 ,31 a difference that may be related to variations in sample characteristics, such as age, sex and weight at baseline. Weight gain was more significant in the first month of treatment, with a deceleration over time, as expected. 31, 32 As the more pronounced weight gain was observed within 1 month, it can mostly be attributed to drug effect and not to normal physical development. Although weight gain lessens with long-term use of risperidone, it is still a risk factor for many health problems, such as heart disease, hypertension, dyslipidemia and diabetes, and should be closely monitored.
Prolactin elevation was also a common adverse effect observed in our study. Although this variation diminished over time in our population sample, a mean fivefold increase in prolactin levels was still observed after 6 months of treatment, higher than reported earlier by other authors. 33, 34 Although it is possible that prolactin levels continue to decline with more extended treatment, the impact of chronic prolactin increase on gonadal hormones and overall development, especially in a paediatric population, is currently unknown and is a major concern of researchers and clinicians.
Our results using the generalized estimating equation analysis showed that, after correcting for confounding factors including sex, age, dosage, treatment duration and baseline response values, several genetic factors affect risperidone efficacy and the observed ADRs.
Improvement of the patients under risperidone therapy, measured by the decline in ATEC scores, was shown to be influenced by the HTR2A c.-1438G4A, ABCB1 c.1236C4T, DRD3 p.S9G and the HTR2C c.-995G4A markers. In general, interpreting these findings is at present still difficult, as the functional effect of some of these polymorphisms is not fully elucidated, and there are many earlier reports of discrepant results that may be attributed to study sample differences in ethnicity, sex ratio, age range and/or study design (reviewed in 9 ). In this study, patients homozygous for the HTR2A-1438G allele showed a poorer response to risperidone, as described earlier in schizophrenic patients. 35, 36 A decrease in promoter activity of the -1438G allele relative to the A allele results in lower density of these receptors in the brain. 37, 38 The poorer response to risperidone observed in patients homozygous for the low expression G allele may therefore be explained by a lower availability of the 5-HT2A receptors and consequent decreased effectiveness of the drug. Another polymorphism in this gene, HTR2A 102T4C, has been more extensively studied. The results of a meta-analysis in Caucasian patients reported that the 102C allele, in complete linkage disequilibrium with the -1438G allele, is associated with poor antipsychotic response, reinforcing the findings in our data sample. 39 Three common ABCB1 polymorphisms, c.1236C4T, c.2677G4T/A and c.3435C4T have been extensively studied and repeatedly shown to predict changes in the expression and function of P-glycoprotein. 40 Our results show that the ABCB1 c.1236C4T polymorphism influences risperidone clinical improvement, with patients carrying the T allele showing better improvement, in agreement with an earlier study. 41 The 1236T allele, which has been associated with lower expression and function of P-glycoprotein in the blood-brain barrier and in the small intestine, [42] [43] [44] would lead to a lower efflux of risperidone and hence higher drug concentration in the brain, therefore explaining the better outcome of the patients carrying this allele. The silent Abbreviations: EM, extensive metabolizers; PM, poor metabolizers, UM, ultra-rapid metabolizers. The HTR2C gene maps on the X chromosome.
CT Correia et al polymorphism c.3435C4T, which is in strong LD with c.1236C4T, was not associated with risperidone efficacy in our study, although it has been shown to be associated with olanzapine response. [45] [46] [47] The difference in drugs is likely not the reason for the discrepant results, because risperidone has a higher affinity for P-glycoprotein than olanzapine and thus a stronger effect would be expected. 10 It is not clear which of the ABCB1 polymorphisms is functional, and variable patterns of LD in the region can lead to different association results. Haplotype analysis would be useful to identify the genetic variants that have a role in drug response, but given our small sample size could not be carried out.
A poorer therapeutic response to risperidone was associated with the DRD3 TT genotype. Recent studies have focused on the influence of the Ser9Gly polymorphism of the DRD3 gene on clinical response to risperidone, but the results were inconclusive, suggesting other functional variants in this gene may be in LD with this polymorphism. [48] [49] [50] An association between clinical efficacy of risperidone treatment and the HTR2C-c.995G4A promoter polymorphism was established. Although most of the earlier studies have focused on the role of this gene in weight gain (reviewed in 9 ), the association of the higher expression 995G allele 51 with better improvement indicates that the antagonism of this receptor might be important for the risperidone antipsychotic therapeutic action.
Concerning the occurrence of ADRs, both CYP2D6 and HTR2C c.C33S polymorphisms have been identified in this study as important predictors of risperidone-induced increase in BMI and waist circumference. CYP2D6 ultrarapid metabolizers have a significantly lower propensity to waist circumference and BMI increase. The smaller increase in waist circumference observed also for poor metabolizers might be an artefact because of the small number of individuals with this phenotype. Our results show that the CYP2D6 status influences risperidone treatment. The lower risperidone to 9-hidroxyrisperidone ratio that characterizes the ultra-rapid metabolizers phenotype may explain the lower propensity of this phenotype to induce weight gain because of the differences in the affinity of these compounds for the receptors that might be involved in weight regulation, such as 5-HT2C. 52 Homozygoty or hemizygoty for the C allele of the HTR2C p.C33S polymorphism was also associated with a smaller increase in BMI and waist circumference, although the functional effect of this poly- The presence of the HTR6 rs9659997C allele, the BDNF p.V66M A allele, the HTR2C p.C23S C allele or the HTR2A-1438GG genotype was associated with a higher prolactin increase. Risperidone-induced hyperprolactinemia is mainly derived from the blockage of D2 receptors, which abolishes the dopamine-inhibiting effect on prolactin synthesis. Contrary to dopamine, serotonin is known to stimulate prolactin secretion and its antagonists decrease prolactin concentration. 56 5-HT2A and 2C receptors are involved in the release of prolactin, and agonists of these receptors increase the secretion of this hormone. 57, 58 The antagonistic effect exerted by risperidone on these receptors will inhibit prolactin secretion, therefore counteracting the increase induced by risperidone binding to D2 receptors. The presence of a HTR2A-1438G allele leads to a lower density of these receptors, 37, 38 resulting in higher prolactin secretion and increased levels of this hormone in patients homozygous for this allele, and also to a diminished therapy response (as described above). On the other hand, the lack of association with the DRD2 gene, in agreement with earlier studies, 33, 59, 60 reinforces the idea that the serotonin receptors have a more important function in regulating prolactin secretion induced by risperidone than by other drugs because of the differences in the pharmacodynamic profile between risperidone and other atypicals, such as clozapine and olanzapine. The role of BDNF as a potent 5-HT survival and growth factor likely explains the association between the BDNF polymorphism Val66Met and prolactin elevation. 61 This study aimed at identifying genetic contributors to the clinical variability in risperidone response of autistic patients. The results presented here are still preliminary and should be interpreted with caution because of the small sample size. A related limitation of this study is the lack of correction for multiple testing. In a relatively small sample size, like ours, the application of correction methods may result in an excess of type II errors, thus overlooking true associations with a consequent loss of power. In spite of these limitations, this study has several strengths that overcome limitations presented by other pharmacogenetic studies. Although many studies have focused on the involvement of single polymorphisms in individual aspects of risperidone therapy, a comprehensive assessment taking into account the symptomatology, clinical improvement and adverse effects, as well as multiple candidate genes, has not been reported. An important point is that patients involved in this study were receiving antipsychotics for the first time and were only medicated with risperidone during this study. Previous drug treatment may produce confounding effects on clinical response to subsequent antipsychotic medications. In particular, it has been found that long-term treatment with atypical antipsychotics significantly alters the abundance of specific neurotransmitter receptors. 62 Further, the effects of other potential confounding factors (such as age, sex, drug dosage or treatment duration) were adjusted in the regression analysis, which was not usually performed in older studies. Therapeutic response was evaluated from ATEC scores, rather than dichotomizing the patients into responders and non-responders, because response to antipsychotics is not pharmacogenetically dichotomous. An additional strong point of this work is the longitudinal follow-up of the patients over a long period of time, with measures taken at five different time points.
Longitudinal studies have several advantages: (1) subjects serve as own control; (2) repeated measurements of the same subject reduce measurement error; (3) it is possible to focus on changes occurring within subjects and to make population inferences that are not as sensitive to between-subject variation (4) provide information about individual change. Although having many advantages, longitudinal research also poses several challenges, largely related with the problem of participant attrition, a factor particularly critical in a paediatric population and that generally complicates the collection of large sample sizes, and the need for more computationally intensive and less well-developed methods of analysis to take into account the dependency of the data. The use of generalized estimating equation analysis allowed accommodation of the problem of the non-independence of the data, offering a good solution to problems often encountered in analysing longitudinal data. In summary, we conducted a detailed association study of several candidate genes with risperidone efficacy and safety measures and identified, for the first time, several genes that may be implicated in efficacy and in the development of risperidone adverse effects in autism patients. Owing to limited sample size, the usefulness of the results in a clinical context is still limited, and the present data need to be replicated in larger sample populations and different ethic groups. To fully elucidate the relationship between these polymorphisms and risperidone response, an analysis of the interaction effect between genes or genes and environmental factors is also warranted; this will ultimately enable the development of an algorithm incorporating clinical parameters together with the patient's genotype, to predict an appropriate dose for individual patients. This study thus makes a preliminary contribution to the personalized therapeutics of risperidone in autism, supporting the promise that pharmacogenetic testing may be used in the future to establish optimal doses and to identify early subjects at risk for adverse reactions.
